Nuvalent, Inc. Class A NUVL 深 滬
已收盤 02-06 16:00:00 美东时间
103.59
+2.690
+2.67%
華盛通- 最 高104.40
- 今 開102.21
- 成交量 56.65万股
- 最 低 101.12
- 昨 收 100.90
- 總市值 80.45亿
- 52周最高 113.015
- 市盈率 靜 --
- 換手率 0.73%
- 52周最低 55.535
- 委 比 12.98%
- 總股本 7765.72万
- 歷史最高 113.51
- 量 比 1.04
- 振 幅 3.25%
- 歷史最低 7.09
- 每 手 1
- 風險率 12.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvalent Eyes First US Drug Launch in 2026, Lays Out 2026 FDA Filings and Commercial Launch Plans With $1.4B Cash Runway
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline
01-12 19:34
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
JP Morgan Maintains Overweight on Nuvalent, Lowers Price Target to $145
JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and lowers the price target from $147 to $145.
2025-12-20 00:22
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Nuvalent New Drug Application For Zidesamtinib ROS1-Selective Inhibitor Reeives FDA's Approval To Treat Locally Advanced Or Metastatic Ros1-positive Non-small Cell Lung Cancer
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food and Drug
2025-11-20 05:22
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Nuvalent Announces $500M Class A Common Stock Offering
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an
2025-11-18 05:02
Nuvalent Announces Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically prov...
2025-11-18 05:01
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
